Inactive Instrument

Millendo Therapeutics

Equities

MLND

US60040X1037

Biotechnology & Medical Research

Millendo Therapeutics, Inc. Announces Resignation of Dr. Pharis Mohideen as Chief Medical Officer, Effective on July 12, 2019

June 18, 2019 at 08:46 am EDT

On June 13, 2019, Dr. Pharis Mohideen notified Millendo Therapeutics, Inc. that he will be resigning from his position as Chief Medical Officer of the company, effective July 12, 2019. He has informed the company that he will be pursuing his career closer to his home in New Jersey, allowing him to spend more time with his family.

Latest news about Millendo Therapeutics

Millendo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Millendo Therapeutics, Inc. and Tempest Therapeutics, Inc. Enter into First Amendment to Loan and Security Agreement	22-12-29	CI
Millendo Therapeutics, Inc. Joins Nicholas Maestas as Vice President, Strategy and Finance and It's Principal Financial Officer	21-09-30	CI
Millendo Therapeutics, Inc.(NasdaqCM:MLND) dropped from NASDAQ Composite Index	21-06-25	CI
Tempest Therapeutics Inc. completed the acquisition of Millendo Therapeutics, Inc. in a reverse merger transaction for approximately $180 million.	21-06-24	CI
Millendo Therapeutics : , Tempest Therapeutics Investors Approve Merger Proposals	21-06-22	MT
Millendo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-13	CI
Transcript : Millendo Therapeutics, Inc., Tempest Therapeutics Inc. - M&A Call	21-03-29
Millendo Therapeutics : Tempest, Millendo Agree to Merge, Combined Company to List on NASDAQ	21-03-29	MT
Millendo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-29	CI
Tempest Therapeutics Inc. entered into a definitive agreement and plan of merger to acquire Millendo Therapeutics, Inc. in a reverse merger transaction.	21-03-28	CI
Millendo Therapeutics, Inc. Announces Executive Changes	21-01-28	CI
Millendo Therapeutics, Inc. Plans to Reduce Its Workforce with Majority of Reduction in Personnel Expects to Complete by April 15, 2021	21-01-28	CI
MILLENDO THERAPEUTICS : Ladenburg Thalmann Downgrades Millendo Therapeutics to Neutral from Buy	21-01-06	MT
MILLENDO THERAPEUTICS : SVB Leerink Downgrades Millendo Therapeutics to Market Perform From Outperform; Price Target is $2	21-01-06	MT
Millendo Therapeutics, Inc. Announces Discontinue Further Investment in MLE-301	21-01-05	CI
Millendo Therapeutics, Inc. announced that it expects to receive $89 million in funding	20-11-14	CI
MILLENDO THERAPEUTICS : Wedbush Adjusts Price Target for Millendo Therapeutics to $2 From $3, Maintains Neutral Rating	20-11-09	MT
Millendo Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-09	CI
Millendo Therapeutics Announces Initiation of First-In-Human Clinical Trial of MLE-301, A Selective NK3R Antagonist	20-09-24	CI
Millendo Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-10	CI
Millendo Therapeutics, Inc.(NasdaqCM:MLND) added to Russell Microcap Value Index	20-06-29	CI
Millendo Therapeutics, Inc.(NasdaqCM:MLND) dropped from Russell 2000 Dynamic Index	20-06-29	CI
Millendo Therapeutics, Inc.(NasdaqCM:MLND) dropped from Russell 2000 Index	20-06-26	CI
Millendo Therapeutics, Inc.(NasdaqCM:MLND) dropped from Russell 3000 Growth Index	20-06-26	CI

Chart Millendo Therapeutics

Duration

Period

More charts

Company Profile

Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company's two clinical programs are TPST-1495 and TPST-1120. The Company's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+48.77%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research